Posted in | News

American Superconductor Takes 20% Stake in One Of New Zealand's Leading Technology Companies

American Superconductor Corporation, has announced it has taken a 20 percent equity position in HTS-110, a new business derived from Industrial Research Limited, one of New Zealand's leading technology companies. HTS-110 will design and manufacture HTS electromagnetic coils, magnets and other HTS devices for end users and original equipment manufacturers exclusively utilizing AMSC's HTS wire.

The non-cash transaction consists of transferring AMSC's CryoSaver(R) current leads business to HTS-110, granting non-exclusive licenses to certain coil patents, and providing training for current lead and magnet design and fabrication. "We are creating a new business that will meet the growing global demand for HTS components for a wide array of applications," said Geoff Todd, chief executive of HTS-110. "More companies worldwide are seeking ways to use HTS technology to improve their products.

Initially, HTS-110 is targeting markets in the U.S., Japan and Europe. "We are delighted to enter into this business relationship with HTS-110," said David Paratore, president and chief operating officer of AMSC. "We believe HTS-110 is well positioned to help expand the market for HTS products around the world providing AMSC an additional opportunity to increase HTS wire sales." Paratore commented that AMSC is not restricted in selling HTS wire to other companies and will continue to sell to customers who are developing their own HTS components and products that incorporate HTS wire.

For more information on magnets

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.